Effect of alfuzosin on female primary bladder neck obstruction

Int Urogynecol J Pelvic Floor Dysfunct. 2009 Feb;20(2):217-22. doi: 10.1007/s00192-008-0749-x. Epub 2008 Nov 4.


Our objective was to assess the effect of the selective alpha(1)-blocker alfuzosin on urodynamic parameters and quality of life in female patients with primary bladder neck obstruction (PBNO). Twenty-five women identified as having PBNO were included in the study. After the initial assessment of urodynamic parameters and bother score index, all patients were treated with alfuzosin 5 mg twice daily for 8 weeks. After this period of time, the patients were reassessed with the same methodology as pretreatment. Symptoms subjectively improved, and patients' satisfaction significantly increased in 64% of the patients (16 out of 25). Most urodynamic parameters were also significantly improved after treatment with alfuzosin. Alfuzosin significantly improved urodynamic parameters and alleviated bother score in almost two thirds of patients with PBNO and can be an effective first-line treatment of this situation.

Publication types

  • Clinical Trial

MeSH terms

  • Adrenergic alpha-Antagonists / pharmacology
  • Adrenergic alpha-Antagonists / therapeutic use*
  • Female
  • Humans
  • Middle Aged
  • Patient Satisfaction
  • Prospective Studies
  • Quality of Life
  • Quinazolines / pharmacology
  • Quinazolines / therapeutic use*
  • Treatment Outcome
  • Urinary Bladder Neck Obstruction / complications
  • Urinary Bladder Neck Obstruction / drug therapy*
  • Urination Disorders / drug therapy*
  • Urination Disorders / etiology
  • Urodynamics / drug effects


  • Adrenergic alpha-Antagonists
  • Quinazolines
  • alfuzosin